Navigation Links
Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
Date:1/6/2014

DURHAM, N.C., Jan. 6, 2014 /PRNewswire/ -- Scioderm, Inc. today announced the initiation of a Phase 2B study designed to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a rare, genetic connective tissue disorder that typically manifests at birth or early childhood.

"People affected by EB suffer skin blisters, chronic wounds, almost constant pain and itching, and scarring," said Robert Ryan., Ph.D., President and Chief Executive Officer of Scioderm. "The current standard of care is palliative only and focuses primarily on daily wound care, bandaging and pain management. We believe SD-101 has the potential to initiate and continue healing of lesions in this patient population, and Scioderm is committed to develop SD-101 as expeditiously as possible as a treatment option for patients suffering from this devastating condition."

SD-101 for the treatment of EB has been granted an orphan drug designation in the US and in December 2013 received a positive opinion by the Committee for Orphan Medicinal Products (COMP) in the EU.  In addition, Scioderm was the first biotech to receive "Breakthrough Therapy" designation for SD-101 from the Food and Drug Administration (FDA) for the treatment of skin effects in patients with EB.  A breakthrough therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program. In addition, Scioderm was recently selected as  a 2013 "Fierce Top 15" company by FierceBiotech, considered as one of the top 15 emerging companies in the biotech industry. 

The Phase 2B study (SD-003) is a multi-site, prospective, randomized, placebo-controlled trial evaluating the efficacy and safety of SD-101 to close selected chronic cutaneous wounds and reduction in body surface area (
'/>"/>

SOURCE Scioderm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
2. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
3. Scioderms SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year 2015 results on Thursday, January 22, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:12/19/2014)... Dec. 18, 2014 Since last month,s FBI ... now known as the leading online black market for ... growth in its offering of drugs and other illegal ... the takedowns did succeed in lowering the numbers of ... of the markets in August. But some new sites ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... April 25, 2007 /PRNewswire-USNewswire/ -- At least,one-third of ... in childhood or adolescence. However, in children, it ... of other,disorders, notes the May 2007 issue of ... children, usually do not show the,adult cycle of ...
... GmbH (Langenfeld,Germany), a specialty pharmaceutics company announces ... for their proprietary,Sufentanil transdermal patch. , “Today, ... of the second clinical trial for our ... to complete this study in,the first half ...
Cached Medicine Technology:Bipolar Disorder in Children Difficult to Diagnose, Reports the,Harvard Mental Health Letter 2Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2
(Date:12/19/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... Franklin, Ind. The top executive search firm in the ... than 900 healthcare executives into organizations. , Johnson ... providing care to the residents of Johnson County and ...
(Date:12/19/2014)... Sarasota, FL (PRWEB) December 19, 2014 ... witnessed someone having difficulty breathing, you probably wished you ... symptom of asthma, COPD, cystic fibrosis, and other breathing ... are prescription medications and avoiding triggers, but other common ... of Asthma Educators conference in San Antonio, TX, 34 ...
(Date:12/19/2014)... 19, 2014 Consilium Staffing, Your ... AMSUS Society for Federal Health Professionals annual meeting ... industry to military and federal healthcare providers. ... Veterans Small Business Engagement (NVSBE) conference last week ... be a vital solution in addressing our nation’s ...
(Date:12/19/2014)... Norton HealthDay Reporter THURSDAY, ... who were exposed to high levels of air pollution late ... a U.S. study suggests. Researchers found that of nearly ... those exposed to the most air pollution during pregnancy were ... autism. And exposure during the third trimester, specifically, showed the ...
(Date:12/17/2014)... December 17, 2014 While countless companies tempt ... not realize the potential dangers of their purchase. Not only ... from a qualified doctor, but patients who buy hCG online ... that there is actually no real hCG present. Illegal internet ... there are no safety standards and may contain unknown fillers ...
Breaking Medicine News(10 mins):Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3
... and concussions among high school athletes found that proper ... concussion. ,In the current study, ... in Philadelphia and co-author Dr. Tracey Covassin of Michigan ... of athletics from Pennsylvania and New Jersey high schools. ...
... Expanding waistlines has been a burgeoning healthcare problem, which has ... obesity rates, is also the increasing// numbers of myths doing ... subject of obesity has been conducted from time to time. ... has painted a dismal scenario of obesity rates by 2010, ...
... Bollywood actor-turned-politician Shatrughan Sinha, now popular talk show host Shekhar Suman ... state - Bihar. ,Suman has proposed to set ... his son Ayush who died of a heart ailment many years ... forward a proposal to set up an ultra modern heart hospital ...
... prevent more sudden deaths than defibrillators in homes ... to US scientists.// ,Researchers at Regions Hospital ... by food supplementation and by electronic devices in ... the population of Olmsted County, Minn., in 2000. ...
... to be wary of the so-called stem cell wonder cures ... properly tested.// ,The health experts had yesterday in ... as a world leader in stem cell research, but cautioned ... and cosmetic skin treatment were yet to be proven, and ...
... Canada can differ according to provinces, says a new study ... ,People on dialysis in Alberta were four times more ... the study conducted over a five-year period found. Saskatchewan, Atlantic ... for kidneys than Ontario. ,"We can say that ...
Cached Medicine News:Health News:Proper Fitting Of Football Helmets Essential To Prevent Concussion 2Health News:Scientists In UK Issue A Caution Over Untested Stem Cell Treatments 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: